Skip to main content
Journal cover image

Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors.

Publication ,  Journal Article
Chang, EL; Liu, R; Keyhanian, K; Huynh, K; Berkenstock, M; Bhatti, MT; Chen, JJ; Chodosh, J; Costello, F; Dalvin, LA; DeLott, LB; Dinkin, M ...
Published in: J Immunother Cancer
April 8, 2025

Ophthalmic immune-related adverse events (Eye-irAEs) from immune checkpoint inhibitors can cause visual morbidity. The absence of standardized definitions for Eye-irAEs not only impedes the development of evidence-based treatments but also progress in translational research. The objective of this study was to develop consensus guidance for an approach to Eye-irAEs.Four ophthalmic physicians (uveitis specialists and neuro-ophthalmologists) drafted Eye-irAE consensus guidance and definitions, which were reviewed by the multidisciplinary Eye-irAE definition panel. The panel was divided into Group A (Neuro-ophthalmology/Orbital Disease) and Group B (Uveitis/Ocular Surface Disease). A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. For each disorder, five diagnostic components were evaluated: symptoms, examination findings, laboratory studies/imaging findings, diagnostic criteria, and treatment. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free-text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND Corporation/ University of California Los Angeles Health Services Utilization Study (RAND/UCLA) Appropriateness Method with prespecified definitions.29 panelists from 25 academic medical centers voted on 114 rating scales (66 neuro-ophthalmic/orbital disease components, 48 uveitis/ocular surface disease components); of these, 86.3% (57/66) in Group A and 89.6% (43/48) in Group B reached first-round consensus. After revisions, all items except 6.1% (4/66) in Group A and 1.6% (1/60) in Group B received second-round consensus. Consensus definitions were achieved for 10/11 neuro-ophthalmic/orbital disorders: optic neuritis, inflammatory optic disc edema, arteritic ischemic optic neuropathy, optic perineuritis, orbital inflammation, thyroid eye disease-like orbital inflammation, cavernous sinus syndrome, oculomotor mononeuritis, trochlear mononeuritis, and abducens mononeuritis. Consensus definitions were achieved for 9/10 uveitis/ocular surface disorders: anterior uveitis, intermediate uveitis, posterior uveitis, panuveitis, Vogt-Koyanagi-Harada-like syndrome, sarcoidosis-like syndrome, acute macular neuroretinopathy, dry eye disease, and scleritis.These disease definitions establish a standardized classification for Eye-irAE, highlighting differences between irAEs and other inflammatory disorders. Importantly, diagnostic certainty does not always align directly with the need to treat as an Eye-irAE. Given the consensus from this representative panel group, it is anticipated the definitions will be used broadly across clinical and research settings.

Duke Scholars

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

April 8, 2025

Volume

13

Issue

4

Location

England

Related Subject Headings

  • Immune Checkpoint Inhibitors
  • Humans
  • Eye Diseases
  • Delphi Technique
  • Consensus
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chang, E. L., Liu, R., Keyhanian, K., Huynh, K., Berkenstock, M., Bhatti, M. T., … Chwalisz, B. K. (2025). Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer, 13(4). https://doi.org/10.1136/jitc-2024-011049
Chang, Eileen L., Renee Liu, Kiandokht Keyhanian, Katie Huynh, Meghan Berkenstock, M Tariq Bhatti, John J. Chen, et al. “Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors.J Immunother Cancer 13, no. 4 (April 8, 2025). https://doi.org/10.1136/jitc-2024-011049.
Chang EL, Liu R, Keyhanian K, Huynh K, Berkenstock M, Bhatti MT, et al. Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2025 Apr 8;13(4).
Chang, Eileen L., et al. “Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors.J Immunother Cancer, vol. 13, no. 4, Apr. 2025. Pubmed, doi:10.1136/jitc-2024-011049.
Chang EL, Liu R, Keyhanian K, Huynh K, Berkenstock M, Bhatti MT, Chen JJ, Chodosh J, Costello F, Dalvin LA, DeLott LB, Dinkin M, Egan RA, Fraser CL, Freitag SK, Gangaputra S, Gordon LK, Guidon AC, Johnson DB, Kombo N, Kramer M, Lee AG, Levy M, Lobo-Chan A-M, Mantopoulos D, Papaliodis G, Pless M, Pimkina J, Rubin KM, Sen HN, Shariff A, Subramanian PS, Tsui E, Yoon MK, McDunn J, Rine J, Reynolds KL, Sobrin L, Chwalisz BK. Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2025 Apr 8;13(4).
Journal cover image

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

April 8, 2025

Volume

13

Issue

4

Location

England

Related Subject Headings

  • Immune Checkpoint Inhibitors
  • Humans
  • Eye Diseases
  • Delphi Technique
  • Consensus
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology